Emerald Acquisition Ltd. purchased a new position in Sarepta Therapeutics Inc. (NASDAQ:SRPT) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 26,004 shares of the company’s stock, valued at approximately $496,000. Emerald Acquisition Ltd. owned 0.06% of Sarepta Therapeutics as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in the company. TIAA CREF Investment Management LLC boosted its position in Sarepta Therapeutics by 5.5% in the first quarter. TIAA CREF Investment Management LLC now owns 216,707 shares of the company’s stock worth $4,230,000 after buying an additional 11,334 shares during the last quarter. Franklin Resources Inc. acquired a new position in Sarepta Therapeutics during the first quarter worth $13,506,000. BlackRock Fund Advisors boosted its position in shares of Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock worth $32,439,000 after buying an additional 36,371 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in shares of Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock worth $20,865,000 after buying an additional 25,799 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock worth $48,168,000 after buying an additional 865,658 shares during the last quarter. 65.06% of the stock is owned by institutional investors.
Sarepta Therapeutics Inc. (NASDAQ:SRPT) traded down 3.07% on Wednesday, reaching $48.35. The company had a trading volume of 803,257 shares. The stock’s 50-day moving average price is $46.30 and its 200 day moving average price is $27.13. The firm’s market capitalization is $2.32 billion. Sarepta Therapeutics Inc. has a 52-week low of $8.00 and a 52-week high of $63.73.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter in the prior year, the business posted ($0.87) EPS. On average, equities analysts anticipate that Sarepta Therapeutics Inc. will post ($4.23) earnings per share for the current fiscal year.
A number of brokerages have commented on SRPT. Oppenheimer Holdings Inc. reissued a “buy” rating and set a $60.00 target price on shares of Sarepta Therapeutics in a report on Sunday, July 17th. Jefferies Group set a $58.00 target price on Sarepta Therapeutics and gave the company a “hold” rating in a report on Sunday, October 2nd. JMP Securities reissued an “underperform” rating and set a $10.00 target price on shares of Sarepta Therapeutics in a report on Thursday, September 15th. Wedbush reissued an “outperform” rating and set a $66.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, September 20th. Finally, Piper Jaffray Cos. set a $68.00 target price on Sarepta Therapeutics and gave the company a “buy” rating in a report on Tuesday, October 4th. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $63.54.
In other Sarepta Therapeutics news, CEO Edward M. Md Kaye sold 24,557 shares of the firm’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total value of $736,710.00. Following the sale, the chief executive officer now owns 76,983 shares in the company, valued at $2,309,490. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP David T. Howton sold 9,304 shares of the firm’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $50.00, for a total transaction of $465,200.00. Following the completion of the sale, the senior vice president now owns 11,168 shares in the company, valued at approximately $558,400. The disclosure for this sale can be found here. 10.90% of the stock is currently owned by company insiders.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc. (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.